Effects of Post-COVID-19 on Quadriceps Femoral Muscle-tendon Unit
NCT ID: NCT04961255
Last Updated: 2023-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
90 participants
OBSERVATIONAL
2021-08-24
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Healthy individuals will be evaluated only once throughout the study. Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated.
No interventions assigned to this group
COVID-19 positive participants who had moderate symptoms group
These participants will be evaluated 4 times throughout the study.
Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.
Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.
Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.
Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.
Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment.
No interventions assigned to this group
COVID-19 positive participants who had severe symptoms group
These participants will be evaluated 4 times throughout the study.
Baseline 1: This will be performed between 21 to 30 days after the onset of symptoms of COVID-19 infection.
Assessment 2: This will be performed between 31 to 90 days after the onset of symptoms of COVID-19 infection.
Assessment 3: This will be carried out between 91 and 180 days after the onset of symptoms of COVID-19 infection.
Assessment 4: This will be performed between 181 to 360 days after the onset of symptoms of COVID-19 infection.
Inflammatory markers, the isometric maximum voluntary force of knee extensor torque, muscle fatigue, neuromuscular adaptations, muscle architecture, quadriceps tendon properties, peripheral oxygen extraction, and body composition will be evaluated in each assessment.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- The control group will include healthy participants, aged 18 and 80 years, who had not tested positive for COVID-19.
* COVID-19 positive participants who had moderate symptoms group:
* Female and male participants, aged between 18 and 80 years, who had Molecular test (RT-PCR) or serological test, which assesses whether the samples are reactive to immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, positive for COVID-19;
* Presence of some of the following symptoms, without the need for hospitalization: dry cough, runny nose, sore throat, diffuse body pain, persistent hyperthermia, no hypoxemia.
* COVID-19 positive participants who had severe symptoms group:
* Female and male participants, aged between 18 and 80 years, who had Molecular test (RT-PCR) or serological test (which assesses whether the samples are reactive to IgM and IgG antibodies) positive for COVID-19;
* Presence of hypoxemia (peripheral oxygen saturation - SPO2 ≤ 93%) requiring hospitalization with or without intubation, in addition to the symptoms described for the COVID-19 positive participants who had moderate symptoms group.
Exclusion Criteria
* Pregnancy;
* Pain, swelling, dermal damage, deformity, or amputation in the regions to be examined;
* Diagnosis of ankylosing spondylitis, rheumatoid arthritis, severe heart disease, advanced chronic obstructive pulmonary disease, cognitive impairment, chemical dependency, psychiatric illness, or behavioral that makes it difficult to cooperate with the procedures.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Brasilia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
João Luiz Q. Durigan
Physical Therapist, Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
João LQ Durigan, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Brasilia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Brasilia
Brasília, Federal District, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
isabella S Almeida
Role: primary
João LQ Durigan, PhD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Almeida IDS, Ferreira LGJ, Vaz MA, Cipriano Junior G, de Resende MA, Vieira DCL, Costa RR, Babault N, Marqueti RC, Durigan JLQ. Fatigue and neuromuscular function in long COVID: A one-year follow-up study. PLoS One. 2025 Sep 24;20(9):e0332242. doi: 10.1371/journal.pone.0332242. eCollection 2025.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAAE: 45043821.0.0000.8093
Identifier Type: -
Identifier Source: org_study_id